WM

Reply Launches Accelerator 365, a New Offering for Microsoft 365 Modern Work Solutions 

Retrieved on: 
Wednesday, January 10, 2024
Technology, Finance, Consulting, Banking, Other Technology, Professional Services, Data Analytics, Data Management, IOT (Internet of Things), Artificial Intelligence, Valorem, Online, WM, Cloud computing, STAR, Multimedia, Microsoft, Insurance, Consultant, Transport, AI, Communication, SharePoint, Google Analytics, Internet, Accelerator, Directory, EXM, Businessperson

View the full release here: https://www.businesswire.com/news/home/20240110817597/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240110817597/en/
    With a variety of enterprise-ready apps and solutions, Accelerator 365 enhances organisations' SharePoint and Viva Connections intranet.
  • “Accelerator 365 is a great opportunity for us to bring together our industry-leading expertise and passionate consultants into a dedicated and focussed Microsoft 365 product team.
  • The Accelerator 365 apps have delivered incredible value to our existing clients, meeting the evolving needs and expectations of organisations and users in the Modern Work space.
  • Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media.

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia

Retrieved on: 
Monday, January 8, 2024
Sequela, Quality of life, Febrile neutropenia, WM, Death, Anemia, International, IWMF, Disease, Neutropenia, NDA, WAM, News, Cancer, Thrombocytopenia, SCR, Macroglobulinemia, MCI, MRR, Mayo Clinic, Mitt, Patient, Safety, Medicine, Cytopenia, Immunoglobulin M, Pharmaceutical industry

The CLOVER WaM study met its primary endpoint with a major response rate (MRR) of 61% (95% confidence interval [44.50%, 75.80%, two-sided p value

Key Points: 
  • The CLOVER WaM study met its primary endpoint with a major response rate (MRR) of 61% (95% confidence interval [44.50%, 75.80%, two-sided p value
  • Notably, iopofosine monotherapy achieved an 8% stringent complete remission (sCR) in this highly refractory WM population.
  • “The results from this pivotal study utilizing just four doses of iopofosine monotherapy in heavily pretreated patients are very compelling, demonstrating deep and durable remissions.
  • “Iopofosine’s high major response rate and achievement of the study’s primary endpoint in highly refractory, Waldenstrom’s macroglobulinemia patients exhibits its potentially practice-changing clinical profile.

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Tuesday, November 14, 2023
Sale, Associate, Translation, Research, Safety, Foreign investment, Food, Transaction, WM, First grade, CRS, IND, Disease, Glioblastoma, Risk, Waldenström macroglobulinemia, Clinical trial, GBM, Patient, CD19, Nature, FDA, Follicular lymphoma, University of Washington, Chronic lymphocytic leukemia, File, Mustang, Diagnosis, University, Mustang Bio, Cancer, Society, CFIUS, Letter, DSM-IV codes, Lymphoma, AACR, Cytokine release syndrome, Indolent lymphoma, Pharmaceutical industry, Cryptocurrency, Video game

WORCESTER, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter that ended September 30, 2023.

Key Points: 
  • WORCESTER, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter that ended September 30, 2023.
  • Subsequent to the end of the third quarter, Mustang raised approximately $4.4 million of gross proceeds in a registered direct offering completed in October 2023.
  • Research and development expenses were $9.5 million for the third quarter of 2023, compared to $15.5 million for the third quarter of 2022.
  • General and administrative expenses were $2.1 million for the third quarter of 2023, compared to $3.4 million for the third quarter of 2022.

WM Announces Plan to Increase its Dividend Rate and a Refreshed $1.5 Billion Share Repurchase Authorization

Retrieved on: 
Monday, December 11, 2023
Professional Services, Trucking, Environmental, Social and Governance (ESG), Other Energy, Transport, Recycling, Green Technology, Oil, Gas, Environment, Energy, Sustainability, Attention, Disclosure, Acquisition, Safety, NYSE, Workforce, Annual report, Investment, Risk, Privacy, Weather, Weakness, Automation, Growth, Failure, Overalls, Recession, WM

WM (NYSE: WM) today announced that its Board of Directors has approved a 7.1% increase in the planned quarterly dividend rate for 2024, from $0.70 to $0.75 per share.

Key Points: 
  • WM (NYSE: WM) today announced that its Board of Directors has approved a 7.1% increase in the planned quarterly dividend rate for 2024, from $0.70 to $0.75 per share.
  • The annual dividend rate increase from $2.80 to $3.00 per share marks the twenty-first consecutive year of dividend rate increases.
  • The Company also received authorization from its Board of Directors to repurchase up to $1.5 billion of the Company’s common stock, superseding the authority remaining under the prior $1.5 billion authorization announced in 2022.
  • “The strong and consistent cash flow generation of our business allows WM to continue to fund all our capital allocation priorities.

Wynn Resorts, Limited Reports Third Quarter 2023 Results

Retrieved on: 
Thursday, November 9, 2023
Entertainment, Vacation, Lodging, Destinations, Travel, Tourist Attractions, Casino, Gaming, Interest, Corporation, WM, Investment, Tourism, WML, WRF, Debt-to-GDP ratio, Note, WYNN, Resort, Encore Boston Harbor, Wynn Palace, Wynn Las Vegas, Amusement park, Video game, Bank, Wynn Resorts, Limited

Wynn Resorts, Limited (NASDAQ: WYNN) ("Wynn Resorts" or the "Company") today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Wynn Resorts, Limited (NASDAQ: WYNN) ("Wynn Resorts" or the "Company") today reported financial results for the third quarter ended September 30, 2023.
  • Net loss attributable to Wynn Resorts, Limited was $116.7 million for the third quarter of 2023, compared to net loss attributable to Wynn Resorts, Limited of $142.9 million for the third quarter of 2022.
  • "Our third quarter results reflect continued strength across our property portfolio," said Craig Billings, CEO of Wynn Resorts, Limited.
  • Net loss attributable to Wynn Resorts, Limited was $116.7 million for the third quarter of 2023, compared to net loss attributable to Wynn Resorts, Limited of $142.9 million for the third quarter of 2022.

OLLY Welcomes Bryan Ferschinger as Chief Revenue Officer

Retrieved on: 
Tuesday, December 12, 2023
DTC, Mars, Incorporated, SAN, Badger, WM, Food, VMS, Marketing, Friends, Golf, CPG, Fortune 500, Growth, Mental health, Family, MillerCoors, E-Comm, Overalls, Management, Tock

SAN FRANCISCO, Dec. 12, 2023 /PRNewswire/ -- OLLY, the leading wellness benefit corporation, known for innovative benefit-forward supplements, announces the appointment of Bryan Ferschinger as Chief Revenue Officer (CRO). Ferschinger is a seasoned executive with a proven track record in driving growth for both Fortune 500s and start-ups. He joins OLLY to spearhead long-term strategy across marketing, brand, eComm and creative, deepening the brand's ongoing success in pushing category boundaries.

Key Points: 
  • SAN FRANCISCO, Dec. 12, 2023 /PRNewswire/ -- OLLY, the leading wellness benefit corporation, known for innovative benefit-forward supplements, announces the appointment of Bryan Ferschinger as Chief Revenue Officer (CRO).
  • Ferschinger is a seasoned executive with a proven track record in driving growth for both Fortune 500s and start-ups.
  • He joins OLLY to spearhead long-term strategy across marketing, brand, eComm and creative, deepening the brand's ongoing success in pushing category boundaries.
  • Prior to joining OLLY, Ferschinger was the Chief Marketing Officer at Tock, the comprehensive reservation management system.

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
FDA, DSM-IV codes, Translation, Fred Hutchinson Cancer Research Center, Infrared spectroscopy correlation table, Bone marrow, University of Washington, Disclosure, Chronic lymphocytic leukemia, Waldenström, Society, PET-CT, Disease, Cancer, Follicular lymphoma, Mustang, University, DL, NHL, Safety, Patient, Investigational New Drug, Associate, American Society of Hematology, HCL, Lymphoma, Pharmaceutical industry, WM

MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center (“Fred Hutch”).

Key Points: 
  • MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center (“Fred Hutch”).
  • All patients displayed MB-106 expansion, with peak levels between 7-14 days post-infusion, and CAR-T cell persistence is ongoing at 6 months.
  • From a safety perspective, 3 patients experienced Grade 1 cytokine release syndrome and no occurrences of immune effector cell-associated neurotoxicity syndrome were reported.
  • Dose-limiting toxicities (“DLT”) were monitored through day 28, and no DLTs were observed at DL1.

Cellectar Biosciences Partners with Florida Cancer Specialists & Research Institute to Support the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting

Retrieved on: 
Wednesday, October 25, 2023
Oncology, Radiation, FDA, Practitioner, Macroglobulinemia, Food, Waldenström macroglobulinemia, Hematology, Physician, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Waldenström, Health, PDC, Partnership, NDA, Cancer, FCS, Patient, Lymphoma, Pharmaceutical industry, WM

FLORHAM PARK, N.J, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, announced today a partnership with Florida Cancer Specialists & Research Institute, LLC (FCS), a world-class cancer care organization serving oncology patients throughout the state of Florida. Through this partnership, Cellectar and FCS will evaluate and further define unmet needs that exist across the Waldenstrom's macroglobulinemia (WM) treatment landscape within the community oncology setting to advance patient care.

Key Points: 
  • Through this partnership, Cellectar and FCS will evaluate and further define unmet needs that exist across the Waldenstrom's macroglobulinemia (WM) treatment landscape within the community oncology setting to advance patient care.
  • "WM is a rare type of lymphoma with limited treatment options and no established standard of care in relapsed refractory disease.
  • As leaders in medical oncology and hematology, FCS currently manages over 1,000 Waldenstrom’s macroglobulinemia patients.
  • Currently there are limited treatment options with only one approved class of drugs and no established standard of care beyond second-line therapy.

Stock Yards Bancorp Reports Solid Third Quarter Earnings of $27.1 Million or $0.92 Per Diluted Share

Retrieved on: 
Wednesday, October 25, 2023
Sale, Condition, FRB, Treasury, Bank, Federal Home Loan Banks, Government, WM, Construction, History, National Keelung Commercial & Industrial Vocational Senior High School, Pressure, Intangibles, Acquisition, PPP, Financial condition report, Federal Reserve Bank of St. Louis, Federal Reserve Bank, Environment, Growth, Commercial, Marketing, FHLB, Depreciation, Unemployment, Total, Investment, Iron ore, Life insurance, Video game, Insurance, Reinsurance, Cryptocurrency, Online shopping, Trust, Central Kentucky Regional Airport

LOUISVILLE, Ky., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Stock Yards Bancorp, Inc. (NASDAQ: SYBT), parent company of Stock Yards Bank & Trust Company, with offices in Louisville, central, eastern and northern Kentucky, as well as the Indianapolis, Indiana and Cincinnati, Ohio metropolitan markets, today reported earnings of $27.1 million, or $0.92 per diluted share, for the third quarter ended September 30, 2023. This compares to net income of $28.5 million, or $0.97 per diluted share, for the third quarter of 2022. The results for the third quarter of 2023 were highlighted by near-record loan growth, linked quarter deposit growth and strong levels of non-interest income.

Key Points: 
  • “Total loans, excluding PPP loans, increased $559 million, or 11%, over the last 12 months, of which $201 million was achieved during the third quarter.
  • In addition, Wealth Management and Trust (“WM&T) had another strong quarter, with net new business growth outweighing unfavorable market conditions.
  • Deposit balances increased $194 million, or 3%, on the linked quarter, as interest bearing deposits increased $246 million and non-interest bearing deposits contracted by $51 million.
  • Non-interest income increased $36,000 to $22.9 million on the linked quarter, consistent with expansion in treasury management fees and card income.

Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia

Retrieved on: 
Tuesday, October 17, 2023
Caruso, Health care, MS, Economics, Organization, BeiGene, Common stock, Statistics, Medical Affairs Bureau, Rutgers University, Employment, File, University, Novartis, Yoon, Strategic management, Cancer, WM, University of Phoenix, Shenandoah University, NDA, Mathematics, Ernst & Young, Celgene, Ernst, Purdue University, Business administration, Hematology, Doctor of Pharmacy, Health, Patient, Master of Business Administration, Management, Pharmaceutical industry, Pharmacy, Science

FLORHAM PARK, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of targeted drugs for the treatment of cancer, is pleased to announce the appointment of William Yoon, PharmD, MBA/HCM as vice president, medical affairs and Aaditya Nanduri, MS, as vice president, business strategy and analytics ahead of the expected readout of top-line pivotal data for iopofosine I 131 in Waldenstrom’s macroglobulinemia (WM) in Q4 2023.

Key Points: 
  • His expertise includes more than twenty years in Medical Affairs, with a strong emphasis on hematology and oncology.
  • He earned his bachelor's degree in pharmacy from Purdue University and a Doctor of Pharmacy degree from Shenandoah University.
  • Mr. Nanduri brings a wealth of experience in data and operations, acquired through key roles at organizations such as BeiGene, Celgene Corporation, and Ernst & Young.
  • His exceptional ability to extract insights from data to drive highly successful, cost-efficient commercial strategies will play a pivotal role in establishing Cellectar as a leader in the radiotherapeutics domain.